Literature DB >> 21756552

tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.

William M Armstead1, J Willis Kiessling, John Riley, Douglas B Cines, Abd Al-Roof Higazi.   

Abstract

OBJECTIVE: N-methyl-D-aspartate (NMDA)-induced pial artery dilation (PAD) is reversed to vasoconstriction after fluid percussion brain injury (FPI). Tissue type plasminogen activator (tPA) is up-regulated and the tPA antagonist, EEIIMD, prevents impaired NMDA PAD after FPI. Mitogen-activated protein kinase (MAPK), a family of at least three kinases, ERK, p38, and JNK, is also up-regulated after traumatic brain injury (TBI). We hypothesize that tPA impairs NMDA-induced cerebrovasodilation after FPI in a MAPK isoform-dependent mechanism.
METHODS: Lateral FPI was induced in newborn pigs. The closed cranial window technique was used to measure pial artery diameter and to collect cerebrospinal fluid (CSF). ERK, p38, and JNK MAPK concentrations in CSF were quantified by ELISA.
RESULTS: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1. FPI modestly increased p38 and ERK isoforms of MAPK. NMDA-induced PAD was reversed to vasoconstriction after FPI, whereas dilator responses to papaverine were unchanged. tPA, in post-FPI CSF concentration, potentiated NMDA-induced vasoconstriction while papaverine dilation was unchanged. SP 600125 and D-JNKI1, blocked NMDA-induced vasoconstriction and fully restored PAD. The ERK antagonist U 0126 partially restored NMDA-induced PAD, while the p38 inhibitor SB203580 aggravated NMDA-induced vasoconstriction observed in the presence of tPA after FPI. DISCUSSION: These data indicate that tPA contributes to impairment of NMDA-mediated cerebrovasodilation after FPI through JNK, while p38 may be protective. These data suggest that inhibition of the endogenous plasminogen activator system and JNK may improve cerebral hemodynamic outcome post-TBI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756552      PMCID: PMC3523283          DOI: 10.1179/016164110X12807570509853

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  36 in total

Review 1.  Cerebral blood flow and vascular physiology.

Authors:  Monica S Vavilala; Lorri A Lee; Arthur M Lam
Journal:  Anesthesiol Clin North Am       Date:  2002-06

2.  Uncoupling of cerebral blood flow and metabolism after cerebral contusion in the rat.

Authors:  H K Richards; S Simac; S Piechnik; J D Pickard
Journal:  J Cereb Blood Flow Metab       Date:  2001-07       Impact factor: 6.200

3.  Age dependent NMDA contribution to impaired hypotensive cerebral hemodynamics following brain injury.

Authors:  William M Armstead
Journal:  Brain Res Dev Brain Res       Date:  2002-11-15

4.  Influences of secondary injury following traumatic brain injury in developing versus adult rats.

Authors:  S Thomas; F Tabibnia; M U Schuhmann; T Brinker; M Samii
Journal:  Acta Neurochir Suppl       Date:  2000

5.  A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.

Authors:  R E Merchant; M R Bullock; C A Carmack; A K Shah; K D Wilner; G Ko; S A Williams
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 6.  Protein kinase C and cerebral vasospasm.

Authors:  I Laher; J H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2001-08       Impact factor: 6.200

7.  Age dependent endothelin contribution to NOC/oFQ induced impairment of NMDA cerebrovasodilation after brain injury.

Authors:  W M Armstead
Journal:  Peptides       Date:  2001-01       Impact factor: 3.750

8.  Relationship between NOC/oFQ, dynorphin, and COX-2 activation in impaired NMDA cerebrovasodilation after brain injury.

Authors:  Miriam Kulkarni; William M Armstead
Journal:  J Neurotrauma       Date:  2002-08       Impact factor: 5.269

9.  uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil H Bdeir; Yasmina Bdeir; Sherman C Stein; Abd Al-Roof Higazi
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-03       Impact factor: 6.200

10.  N-methyl-d-aspartate-triggered neuronal death in organotypic hippocampal cultures is endocytic, autophagic and mediated by the c-Jun N-terminal kinase pathway.

Authors:  Tiziana Borsello; Karine Croquelois; Jean-Pierre Hornung; Peter G H Clarke
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

View more
  18 in total

1.  Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2012-05-30       Impact factor: 2.448

2.  Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.

Authors:  William M Armstead; John Riley; Serge Yarovoi; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Stroke       Date:  2016-06-28       Impact factor: 7.914

3.  Combination Therapies for Traumatic Brain Injury: Retrospective Considerations.

Authors:  Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

4.  tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury.

Authors:  William M Armstead; John Riley; Serge Yarovoi; Douglas B Cines; Douglas H Smith; Abd Al-Roof Higazi
Journal:  J Neurotrauma       Date:  2012-04-30       Impact factor: 5.269

5.  The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.

Authors:  Maithili Sashindranath; Eunice Sales; Maria Daglas; Roxann Freeman; Andre L Samson; Elisa J Cops; Simone Beckham; Adam Galle; Catriona McLean; Cristina Morganti-Kossmann; Jeffrey V Rosenfeld; Rime Madani; Jean-Dominique Vassalli; Enming J Su; Daniel A Lawrence; Robert L Medcalf
Journal:  Brain       Date:  2012-07-20       Impact factor: 13.501

6.  Glucagon protects against impaired NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after brain injury by activating cAMP protein kinase A and inhibiting upregulation of tPA.

Authors:  William M Armstead; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  J Neurotrauma       Date:  2011-03-04       Impact factor: 5.269

Review 7.  tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS.

Authors:  Linda Fredriksson; Daniel A Lawrence; Robert L Medcalf
Journal:  Semin Thromb Hemost       Date:  2016-09-27       Impact factor: 4.180

Review 8.  Linking traumatic brain injury to chronic traumatic encephalopathy: identification of potential mechanisms leading to neurofibrillary tangle development.

Authors:  Brandon Peter Lucke-Wold; Ryan Coddington Turner; Aric Flint Logsdon; Julian Edwin Bailes; Jason Delwyn Huber; Charles Lee Rosen
Journal:  J Neurotrauma       Date:  2014-04-11       Impact factor: 5.269

Review 9.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

10.  tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1.

Authors:  William M Armstead; Leif-Erik Bohman; John Riley; Serge Yarovoi; Abd Al-Roof Higazi; Douglas B Cines
Journal:  J Neurotrauma       Date:  2013-08-24       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.